I期临床-话题@MedSci

#I期临床#

570篇内容 | 7050人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1652955, encodeId=ac1c165295573, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=爱科百发抗呼吸道合胞病毒新药Ziresovir对住院婴幼儿患者的国际II期临床概念验证试验取得突破性结果, objectType=article, longId=182517, objectId=1d7618251e0b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d7618251e0b, replyNumber=0, likeNumber=74, createdTime=2019-12-21, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d7618251e0b, moduleTitle=爱科百发抗呼吸道合胞病毒新药Ziresovir对住院婴幼儿患者的国际II期临床概念验证试验取得突破性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d7618251e0b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652970, encodeId=3f8a16529e0f1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=tafasitamab一线治疗DLBCL的I期临床研究已正式开展, objectType=article, longId=185457, objectId=3ff918545e72, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ff918545e72, replyNumber=0, likeNumber=60, createdTime=2020-10-15, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ff918545e72, moduleTitle=tafasitamab一线治疗DLBCL的I期临床研究已正式开展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ff918545e72)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653032, encodeId=c5921653032b0, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Lancet：重组腺病毒新冠肺炎疫苗I期临床获得成功, objectType=article, longId=194654, objectId=7603194654f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7603194654f4, replyNumber=0, likeNumber=61, createdTime=2020-10-05, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7603194654f4, moduleTitle=Lancet：重组腺病毒新冠肺炎疫苗I期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7603194654f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653076, encodeId=b6db16530e6d1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=FDA和EMA批准OPT-302治疗湿性AMD的III期临床试验, objectType=article, longId=199865, objectId=756f199865ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=756f199865ac, replyNumber=0, likeNumber=74, createdTime=2021-04-09, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=756f199865ac, moduleTitle=FDA和EMA批准OPT-302治疗湿性AMD的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=756f199865ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653085, encodeId=5c411653085a1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NEJM：NVX-CoV2373新冠肺炎疫苗I-II期临床数据喜人, objectType=article, longId=200219, objectId=a20d20021917, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a20d20021917, replyNumber=0, likeNumber=13, createdTime=2021-02-15, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a20d20021917, moduleTitle=NEJM：NVX-CoV2373新冠肺炎疫苗I-II期临床数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a20d20021917)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652963, encodeId=a4c2165296372, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Lancet：奥贝胆酸治疗非酒精性脂肪性肝炎III期临床获得成功, objectType=article, longId=184494, objectId=2df618449455, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2df618449455, replyNumber=0, likeNumber=71, createdTime=2020-11-06, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2df618449455, moduleTitle=Lancet：奥贝胆酸治疗非酒精性脂肪性肝炎III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2df618449455)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652936, encodeId=9bc0165293655, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=精鼎医药成立早期临床研究联盟，扩大在大中华地区的Ⅰ期临床研究能力, objectType=article, longId=179598, objectId=9c791e9598f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c791e9598f4, replyNumber=0, likeNumber=55, createdTime=2020-08-22, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c791e9598f4, moduleTitle=精鼎医药成立早期临床研究联盟，扩大在大中华地区的Ⅰ期临床研究能力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c791e9598f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653038, encodeId=f06d165303842, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=基因疗法LentiGlobin治疗镰状细胞病：I / II期临床取得积极结果, objectType=article, longId=195867, objectId=ce6c19586e0b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce6c19586e0b, replyNumber=0, likeNumber=61, createdTime=2021-01-12, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce6c19586e0b, moduleTitle=基因疗法LentiGlobin治疗镰状细胞病：I / II期临床取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce6c19586e0b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652979, encodeId=3c7516529e9ab, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功, objectType=article, longId=186029, objectId=4575186029eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4575186029eb, replyNumber=0, likeNumber=82, createdTime=2020-06-16, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4575186029eb, moduleTitle=ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4575186029eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652941, encodeId=fea616529411d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=面肩肱型肌营养不良症（FSHD）：Losmapimod的I期临床试验取得积极结果, objectType=article, longId=180555, objectId=cca71805552c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cca71805552c, replyNumber=0, likeNumber=93, createdTime=2020-07-04, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cca71805552c, moduleTitle=面肩肱型肌营养不良症（FSHD）：Losmapimod的I期临床试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cca71805552c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653040, encodeId=7cd7165304059, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=生物制剂CD24Fc治疗重症COVID-19：III期临床取得积极进展, objectType=article, longId=195933, objectId=588919593321, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=588919593321, replyNumber=0, likeNumber=43, createdTime=2020-11-10, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=588919593321, moduleTitle=生物制剂CD24Fc治疗重症COVID-19：III期临床取得积极进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=588919593321)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652948, encodeId=7228165294844, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=MacroGenics宣布HER2单抗Margetuximab在转移性乳腺癌患者中的III期临床SOPHIA的第二次总体中期生存数据, objectType=article, longId=181811, objectId=3a1a18181105, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a1a18181105, replyNumber=0, likeNumber=0, createdTime=2020-07-22, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a1a18181105, moduleTitle=MacroGenics宣布HER2单抗Margetuximab在转移性乳腺癌患者中的III期临床SOPHIA的第二次总体中期生存数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a1a18181105)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652999, encodeId=2e76165299906, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=leronlimab（PRO 140）治疗新冠肺炎的II期临床试验方案获得IND, objectType=article, longId=189616, objectId=bc9018961683, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc9018961683, replyNumber=0, likeNumber=60, createdTime=2020-10-18, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc9018961683, moduleTitle=leronlimab（PRO 140）治疗新冠肺炎的II期临床试验方案获得IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc9018961683)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652935, encodeId=fcfb16529353f, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=JACC：FDA I期临床试验显示，用于修复心脏的水凝胶可安全注射到人体内, objectType=article, longId=179417, objectId=35521e94171b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35521e94171b, replyNumber=0, likeNumber=76, createdTime=2020-04-11, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35521e94171b, moduleTitle=JACC：FDA I期临床试验显示，用于修复心脏的水凝胶可安全注射到人体内, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35521e94171b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653045, encodeId=1fdf165304518, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=每周一次皮下注射C5补体抑制剂ULTOMIRIS，治疗阵发性睡眠性血红蛋白尿达到了III期临床终点, objectType=article, longId=196488, objectId=a16319648829, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a16319648829, replyNumber=0, likeNumber=87, createdTime=2021-03-21, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a16319648829, moduleTitle=每周一次皮下注射C5补体抑制剂ULTOMIRIS，治疗阵发性睡眠性血红蛋白尿达到了III期临床终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a16319648829)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652945, encodeId=96be165294532, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=辉瑞宣布其口服JAK1抑制剂阿布西替尼治疗特应性皮炎的阳性III期临床结果, objectType=article, longId=181538, objectId=4e6d181538d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e6d181538d7, replyNumber=0, likeNumber=63, createdTime=2020-03-30, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e6d181538d7, moduleTitle=辉瑞宣布其口服JAK1抑制剂阿布西替尼治疗特应性皮炎的阳性III期临床结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e6d181538d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653048, encodeId=ffa7165304879, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Tisotumab Vedotin治疗复发或转移性宫颈癌：II期临床试验取得阳性结果, objectType=article, longId=196814, objectId=693e19681493, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=693e19681493, replyNumber=0, likeNumber=57, createdTime=2021-01-23, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=693e19681493, moduleTitle=Tisotumab Vedotin治疗复发或转移性宫颈癌：II期临床试验取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=693e19681493)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652984, encodeId=6d67165298482, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=帕金森治疗或迎突破！CCR3抑制剂AKST4290开始II期临床试验, objectType=article, longId=187514, objectId=65e518e5149c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65e518e5149c, replyNumber=0, likeNumber=52, createdTime=2020-11-27, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65e518e5149c, moduleTitle=帕金森治疗或迎突破！CCR3抑制剂AKST4290开始II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65e518e5149c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652939, encodeId=63ce16529390b, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NEJM：完胜Humira！武田Entyvio治疗UC的III期临床进一步结果出炉, objectType=article, longId=180261, objectId=29ed18026114, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29ed18026114, replyNumber=0, likeNumber=41, createdTime=2020-04-11, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29ed18026114, moduleTitle=NEJM：完胜Humira！武田Entyvio治疗UC的III期临床进一步结果出炉, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29ed18026114)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653058, encodeId=f564165305873, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Lancet：Ad5载体COVID-19疫苗II期临床获得成功, objectType=article, longId=197965, objectId=961319e965b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=961319e965b0, replyNumber=0, likeNumber=62, createdTime=2020-12-13, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=961319e965b0, moduleTitle=Lancet：Ad5载体COVID-19疫苗II期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=961319e965b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床

2020-05-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

爱科百发抗呼吸道合胞病毒新药Ziresovir对住院婴幼儿患者的国际II期临床概念验证试验取得突破性结果

2019-12-21

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

tafasitamab一线治疗DLBCL的I期临床研究已正式开展

2020-10-15

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Lancet：重组腺病毒新冠肺炎疫苗I期临床获得成功

2020-10-05

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

FDA和EMA批准OPT-302治疗湿性AMD的III期临床试验

2021-04-09

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NEJM：NVX-CoV2373新冠肺炎疫苗I-II期临床数据喜人

2021-02-15

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Lancet：奥贝胆酸治疗非酒精性脂肪性肝炎III期临床获得成功

2020-11-06

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

精鼎医药成立早期临床研究联盟，扩大在大中华地区的Ⅰ期临床研究能力

2020-08-22

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

基因疗法LentiGlobin治疗镰状细胞病：I / II期临床取得积极结果

2021-01-12

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功

2020-06-16

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

面肩肱型肌营养不良症（FSHD）：Losmapimod的I期临床试验取得积极结果

2020-07-04

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

生物制剂CD24Fc治疗重症COVID-19：III期临床取得积极进展

2020-11-10

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

MacroGenics宣布HER2单抗Margetuximab在转移性乳腺癌患者中的III期临床SOPHIA的第二次总体中期生存数据

2020-07-22

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

leronlimab（PRO 140）治疗新冠肺炎的II期临床试验方案获得IND

2020-10-18

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

JACC：FDA I期临床试验显示，用于修复心脏的水凝胶可安全注射到人体内

2020-04-11

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

每周一次皮下注射C5补体抑制剂ULTOMIRIS，治疗阵发性睡眠性血红蛋白尿达到了III期临床终点

2021-03-21

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

辉瑞宣布其口服JAK1抑制剂阿布西替尼治疗特应性皮炎的阳性III期临床结果

2020-03-30

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Tisotumab Vedotin治疗复发或转移性宫颈癌：II期临床试验取得阳性结果

2021-01-23

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

帕金森治疗或迎突破！CCR3抑制剂AKST4290开始II期临床试验

2020-11-27

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NEJM：完胜Humira！武田Entyvio治疗UC的III期临床进一步结果出炉

2020-04-11

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Lancet：Ad5载体COVID-19疫苗II期临床获得成功

2020-12-13

科室
- - 订阅+
  - 更多科室
工具
服务